Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
Crossref DOI link: https://doi.org/10.1007/s10147-016-1052-3
Published Online: 2016-10-17
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yamamoto, Noboru
Goto, Koichi
Nishio, Makoto
Chikamori, Kenichi
Hida, Toyoaki
Maemondo, Makoto
Katakami, Nobuyuki
Kozuki, Toshiyuki
Yoshioka, Hiroshige
Seto, Takashi
Tajima, Kosei
Tamura, Tomohide
License valid from 2016-10-17